A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer

BACKGROUND: The clinical challenges of triple-negative breast cancer (TNBC) includes the lack of targeted therapy and chemoresistance. TNBC has relatively high PD-L1 expression, and PD-L1 antibody in combination with nab-paclitaxel has been approved by FDA for TNBC treatment. Aptamers, also termed c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Med Sci Monit
Päätekijät: Wu, Xiaoqiu, Li, Fangfei, Li, Yongshu, Yu, Yuanyuan, Liang, Chao, Zhang, Baoting, Zhao, Chuanzong, Lu, Aiping, Zhang, Ge
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: International Scientific Literature, Inc. 2020
Aiheet:
Lab/In Vitro Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7331476/
https://ncbi.nlm.nih.gov/pubmed/32574155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.925583
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia